Leqembi

Biogen's monoclonal antibody for Alzheimer's disease.

Graphic image of puzzle pieces missing from a persons brain a symbol of degeneration andor the improvement of it
Favicon Fierce Pharma

Anti-amyloid Alzheimer's drugs show 'trivial' effects: report

The anti-amyloid drug class has yielded some FDA approvals and plenty of failures. A new analysis sheds light on how the meds have fared overall.
Eric Sagonowsky Apr 16, 2026 11:36am
Manila folder with CONFIDENTIAL printed on it in red

Alzheimer's trials withheld brain injury risk disclosures: NYT

Oct 24, 2024 11:33am
alzheimers brain neurodegenerative memory head

AbbVie axes Alzheimer's program amid 'evolving landscape'

Jul 25, 2024 10:49am
brain alzheimers dementia neuroscience gears thought think

Lilly's donanemab sails through FDA meeting with 2 yes votes

Jun 10, 2024 5:11pm
brain amyloid alzheimers strings detailed web complicated thought

FDA lays out donanemab concerns, Lilly vigorously defends safety

Jun 6, 2024 10:55am
slipstream contrails aircraft airplanes sky fly miss cross

Lilly glides out of Leqembi slipstream with FDA meeting request

Apr 17, 2024 5:00am